ARCT - Arcturus Therapeutics to establish manufacturing facility for COVID-19 vaccines in Vietnam

Arcturus Therapeutics Holdings (NASDAQ:ARCT) announces an agreement with Vinbiocare Biotechnology Joint Stock Company regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam. Under the terms of the arrangement, Vinbiocare will build out a manufacturing facility in Vietnam, and Arcturus will provide access to proprietary technologies and processes for the manufacture of its COVID-19 vaccines. Arcturus will provide with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam. Vinbiocare will make an upfront payment of $40M and be responsible for costs associated with the technology transfer. Vinbiocare will also pay for mRNA drug substance supplied by Arcturus and royalties on vaccines produced at the Facility. The license and technology transfer applies toward drug product manufacturing but not toward mRNA drug substance manufacturing. Technology transfer is underway.

For further details see:

Arcturus Therapeutics to establish manufacturing facility for COVID-19 vaccines in Vietnam